title: [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
abstract: The term "renal osteodystrophy" has recently been replaced with "CKD-mineral and bone disorder (CKD-MBD)", which includes vascular calcification as well as bone abnormalities. Following this paradigm shift, the Japanese Society for Dialysis Therapy released guidelines for the management of secondary hyperparathyroidism in chronic dialysis patients, which prioritized improvement in survival, but not in bone abnormalities. According to these guidelines, parathyroid intervention, such as parathyroidectomy and percutaneous ethanol injection therapy, should be indicated if mineral disorders cannot be managed by pharmacological means. Recently, several novel therapeutic tools, including sevelamer hydrochloride, calcitriol analogs, and cinacalcet hydrochloride have been introduced in the clinical setting in Japan. The other side 2009 KDIGO guideline suggest that, if the intact PTH levels fall below two times the upper limit of normal for the assay, calcitriol, vitamin D analogs, and/or calcimimetics be reduced or stopped. And in patients with CKD stages 3-5D with severe hyperparathyroidism (HPT) who fail to respond to medical/pharmacological therapy, this guideline suggest parathyroidectomy. Harmonizing these therapeutic modalities and parathyroid interventions, we should expect more effective management of CKD-MBD, leading to the improvement of morbidity and mortality in this patient population. In this part, we consider indication of parathyroid interventions surround the present condition.
authors.affiliation: Uemura Circulation Clinic.
authors.forename: Katsuya
authors.initials: K
authors.lastname: Uemura
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Kakuta
mesh_terms: D001851:Bone Diseases, Metabolic / Q000209:etiology*; D002117:Calcitriol / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use; D002908:Chronic Disease; D000069449:Cinacalcet; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology* / Q000628:therapy*; D007674:Kidney Diseases / Q000150:complications*; D009281:Naphthalenes / Q000627:therapeutic use; D016105:Parathyroidectomy; D011073:Polyamines / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D044169:Receptors, Calcium-Sensing / Q000819:agonists; D000069603:Sevelamer; D014511:Uremia / Q000209:etiology* / Q000628:therapy*; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D002614:Chelating Agents; D009281:Naphthalenes; D011073:Polyamines; D044169:Receptors, Calcium-Sensing; D014807:Vitamin D; D000069603:Sevelamer; D002117:Calcitriol; D000069449:Cinacalcet